Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Holdings Raised by Boston Partners

Boston Partners increased its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report) by 50.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,928 shares of the specialty pharmaceutical company’s stock after buying an additional 3,327 shares during the quarter. Boston Partners’ holdings in Jazz Pharmaceuticals were worth $1,285,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of JAZZ. National Bank of Canada FI raised its position in Jazz Pharmaceuticals by 124.2% during the second quarter. National Bank of Canada FI now owns 1,823 shares of the specialty pharmaceutical company’s stock valued at $226,000 after buying an additional 1,010 shares during the period. Dean Investment Associates LLC acquired a new position in shares of Jazz Pharmaceuticals in the 2nd quarter worth approximately $1,186,000. Los Angeles Capital Management LLC raised its position in Jazz Pharmaceuticals by 558.6% in the 3rd quarter. Los Angeles Capital Management LLC now owns 322,775 shares of the specialty pharmaceutical company’s stock valued at $41,780,000 after purchasing an additional 273,764 shares during the last quarter. BlackRock Inc. raised its position in shares of Jazz Pharmaceuticals by 3.3% during the second quarter. BlackRock Inc. now owns 6,879,285 shares of the specialty pharmaceutical company’s stock worth $852,825,000 after acquiring an additional 222,801 shares during the last quarter. Finally, LSV Asset Management raised its position in shares of Jazz Pharmaceuticals by 2.4% during the third quarter. LSV Asset Management now owns 2,372,177 shares of the specialty pharmaceutical company’s stock worth $307,055,000 after acquiring an additional 55,630 shares during the last quarter. 88.15% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, Director Mark Douglas Smith sold 417 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $119.27, for a total value of $49,735.59. Following the sale, the director now owns 6,888 shares in the company, valued at $821,531.76. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 4.40% of the stock is owned by insiders.

Jazz Pharmaceuticals Stock Up 2.2 %

Shares of NASDAQ:JAZZ opened at $124.71 on Wednesday. Jazz Pharmaceuticals plc has a 52-week low of $111.25 and a 52-week high of $155.03. The firm has a fifty day moving average of $121.72 and a 200 day moving average of $128.00. The firm has a market capitalization of $7.85 billion, a PE ratio of 141.72, a price-to-earnings-growth ratio of 0.93 and a beta of 0.62. The company has a debt-to-equity ratio of 1.46, a quick ratio of 1.67 and a current ratio of 2.06.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Free Report) last issued its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported $4.22 EPS for the quarter, beating the consensus estimate of $4.21 by $0.01. Jazz Pharmaceuticals had a net margin of 2.11% and a return on equity of 22.23%. The firm had revenue of $972.14 million during the quarter, compared to the consensus estimate of $969.47 million. As a group, research analysts anticipate that Jazz Pharmaceuticals plc will post 15.35 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Barclays decreased their price objective on Jazz Pharmaceuticals from $240.00 to $235.00 and set an “overweight” rating for the company in a research note on Monday, January 29th. UBS Group lowered Jazz Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $170.00 to $135.00 in a research note on Monday, November 27th. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 30th. Needham & Company LLC reissued a “buy” rating and set a $225.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, November 29th. Finally, Truist Financial reiterated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, December 4th. Two analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $195.90.

Get Our Latest Research Report on Jazz Pharmaceuticals

About Jazz Pharmaceuticals

(Free Report)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors.

See Also

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.